Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan

Documents similaires

• Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
  par: Mitsuhiro Shikamura, et autres
  Publié: (2024)
• Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with dipeptidyl‐peptidase 4 inhibitor users: A nationwide cohort study in Korea
  par: Hwa Yeon Ko, et autres
  Publié: (2025)
• Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
  par: Hsiao‐Ling Chen, et autres
  Publié: (2024)
• Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
  par: Keiko Maruyama‐Sakurai, et autres
  Publié: (2024)
• Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
  par: Hideaki Hashimoto, et autres
  Publié: (2024)